Betmiga, known generically as mirabegron, is a medication primarily used in the management of overactive bladder (OAB). It functions as a beta-3 adrenergic agonist, which helps relax the bladder muscle, thereby increasing its capacity to hold urine and reducing the frequency of urination, urgent need to urinate, and incidence of incontinence. Betmiga offers an alternative to antimuscarinic drugs for patients with OAB, providing relief from symptoms while typically exhibiting a different side effect profile. It is administered orally, usually once a day, and is noted for its effectiveness in improving the quality of life for individuals suffering from the discomfort and inconvenience associated with overactive bladder. When using Betmiga (mirabegron), a medication commonly prescribed for overactive bladder symptoms, it's crucial to adhere strictly to your doctor's instructions and thoroughly read the label that accompanies the medicine. This ensures you understand the correct dosage and any potential interactions with other medications you may be taking. Always inform your doctor about all other medicines you are using to avoid adverse interactions. Common side effects of Betmiga include hypertension, nasopharyngitis, urinary tract infections, and headache. Although rare, more serious side effects such as angioedema and urinary retention can occur. Due to its potential to cause hypertension, monitoring blood pressure is advisable. Betmiga may also affect your ability to drive or operate machinery, especially if you experience side effects like dizziness or blurred vision. Prioritizing safety by being aware of how Betmiga affects you personally is essential. Always follow your healthcare provider's guidance and report any unusual symptoms or side effects immediately.
Your cart contains products from a separate order category. Adding this product will remove those items from your cart.
Important Supply & Pricing Update about GLP-1 Medications
Due to manufacturer-driven price increases from Eli Lilly and other suppliers, prices for GLP-1 medications including Mounjaro have risen significantly. Global supply constraints may also result in slightly longer lead times.
We remain committed to securing the best possible pricing and supply for our customers and will continue to provide updates as the situationĀ evolves.